Effect of Nicergoline for chronic cerebrovascular insufficiency: a meta analysis
Yujuan Jia, Yuli Hou, Jingtian Hou
Published 2015-10-14
Cite as Chin J Geriatr, 2015, 34(10): 1141-1144. DOI: 10.3760/cma.j.issn.0254-9026.2015.10.025
Abstract
ObjectiveTo systematically review the efficacy and safety of nicergoline on chronic cerebrovascular insufficiency (CCVI).
MethodsDatabases including the Cochrane Library, PubMed, CNKI, VIP and WanFang Date were electronically searched for relevant randomized controlled trails (RCTs) which studied the effectiveness and safety of Nicergoline on chronic cerebrovascular insufficiency. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality. Meta-analysis was performed by using RevMan 5.2 software.
ResultsTotally 9 studies involving 1 030 patients were included. The meta-analysis results showed that, compared with conventional treatment alone, the Nicergoline group was superior in improving the velocity of middle cerebral artery(MCA) in both systolic(MD=16.43, 95%CI: 10.39-22.46) and the late diastolic (MD=11.48, 95%CI: 5.34-17.63). Besides, Nicergoline significantly improved the pulse index (PI) of MCA (MD=-0.37, 95%CI: -0.48- -0.26). Likewise, it obviously improved the velocity in both systolic (MD=11.23, 95%CI: 6.10-16.35), the late diastolic (MD=8.80, 95%CI: 5.20-12.40) and the PI of vertebral artery (VA) (MD=-0.38, 95%CI: -0.47--0.28). The remission rate of the nicergoline group was higher than that of the control group (OR=3.93, 95%CI: 2.66-5.81). Drug-related adverse reactions were not reported in included studies.
ConclusionsNicergoline shows a certain efficacy on CCVI without obvious adverse reactions.
Key words:
Ergolines; Cerebrovascular disorders; Meta-analysis
Contributor Information
Yujuan Jia
Department of Neurology, the First Clinical Medical College of Shanxi Medical University, Taiyuan 030001, China
Yuli Hou
Jingtian Hou
